OR14-1 Pharmacodynamics, Safety, Tolerability, and Efficacy of Oral Insulin Formulation (Oshadi Icp) among Young Adults with Type 1 Diabetes: A Summary of Clinical Studies Phases I, Ib, and Ii

Background Replacement of subcutaneous (SC) insulin by oral insulin for Type I diabetes (T1D) could promote patient compliance and minimize hyperinsulinemia. Oshadi Drug Administration Ltd. has developed an oral carrier for proteins delivery, composed of known ingredients, including polysaccharides...

Descripción completa

Detalles Bibliográficos
Autores principales: Rachmiel, Marianna, Barash, Galia, Leshem, Avital, Sagi, Roy, doenyas-barak, Keren, Koren, Shlomit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Diabetes Mellitus and Glucose Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554863/
http://dx.doi.org/10.1210/js.2019-OR14-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554863/
http://dx.doi.org/10.1210/js.2019-OR14-1

Ejemplares similares